Literature DB >> 7511655

Autoantibody responses to the "native" 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren's syndrome.

J P Buyon1, S G Slade, J D Reveille, J C Hamel, E K Chan.   

Abstract

Abs to the 52-kDa SS-A/Ro protein are found in high prevalence in patients with Sjogren's syndrome (SS) and mothers whose children have the neonatal lupus syndrome (NLS). This study further defines the specificity of this response. By ELISA, 97% of 59 mothers of offspring with NLS had Abs to the 52-kDa recombinant protein compared with 80% in 132 non-NLS sera with anti-SS-A/Ro Abs (p < 0.004). Antigenic regions on the 52-kDa protein were evaluated by immunoprecipitation of [35S]-radiolabeled in vitro translation products. Ninety-five percent of 99 sera that contained anti-52-kDa Abs by ELISA reacted with a large fragment spanning amino acids (aa) 1-291. Two antigenic regions were identified, aa169-291 containing the leucine zipper that was recognized by 83% of the anti-52-kDa sera tested and aa1-78 containing the zinc finger domains that was recognized by only half the sera. No sera immunoprecipitated this N-terminal fragment exclusively. Recognition of one or both regions was not unique to any clinical subset of patients; however, a greater number of sera from patients with SS contained both specificities, whereas asymptomatic mothers whose children had NLS comprised the only clinical group in which the majority recognized the central region of the molecule. Reactivity with both epitopes was demonstrated significantly more often in sera with high titers of Abs to the 60-kDa rSS-A/Ro protein by ELISA in association with the anti-52-kDa response compared with anti-52-kDa responses associated with low titers of anti-60-kDa Abs (p < 0.04). Eighty-one percent of 16 sera that recognized the N-terminal epitope were from patients with the combination of HLA-DRB1*0301, DQA1*0501, and DQB1*0201 alleles, compared with 30% of 10 that recognized only the central epitope (p < 0.02). In summary, this study demonstrates that there are at least two antigenic determinants on the 52-kDa SS-A/Ro protein, one "immunodominant" and the other recognized by a more "restricted" subset of anti-52-kDa SS-A/Ro Abs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511655

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk.

Authors:  J P Buyon; R M Clancy; D M Friedman
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

2.  SS-56, a novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus.

Authors:  O Billaut-Mulot; C Cocude; V Kolesnitchenko; M J Truong; E K Chan; E Hachula; X de la Tribonnière; A Capron; G M Bahr
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  Neonatal lupus: clinical features, therapy, and pathogenesis.

Authors:  L A Lee
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

4.  Interaction cloning and characterization of RoBPI, a novel protein binding to human Ro ribonucleoproteins.

Authors:  P Bouffard; E Barbar; F Brière; G Boire
Journal:  RNA       Date:  2000-01       Impact factor: 4.942

5.  Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block.

Authors:  Robert M Clancy; Petra J Neufing; Ping Zheng; Marguerita O'Mahony; Falk Nimmerjahn; Tom P Gordon; Jill P Buyon
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

6.  The cytoplasmic linker protein CLIP-170 is a human autoantigen.

Authors:  K J Griffith; J P Ryan; J-L Senécal; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

7.  Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study.

Authors:  A G Tzioufas; R Wassmuth; U G Dafni; A Guialis; H-J Haga; D A Isenberg; R Jonsson; J R Kalden; H Kiener; C Sakarellos; J S Smolen; N Sutcliffe; C Vitali; E Yiannaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

8.  Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.

Authors:  Carolina Llanos; Peter M Izmirly; Margaret Katholi; Robert M Clancy; Deborah M Friedman; Mimi Y Kim; Jill P Buyon
Journal:  Arthritis Rheum       Date:  2009-10

9.  Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.

Authors:  Julie Barsalou; Nathalie Costedoat-Chalumeau; Adey Berhanu; Cesar Fors-Nieves; Ummara Shah; Patrick Brown; Carl A Laskin; Nathalie Morel; Kateri Levesque; Jill P Buyon; Earl D Silverman; Peter M Izmirly
Journal:  Ann Rheum Dis       Date:  2018-10-08       Impact factor: 19.103

Review 10.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.

Authors:  Jill P Buyon; Robert M Clancy; Deborah M Friedman
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.